Multi-Omics Phytopharmacology: Integrating Metabolomics, Transcriptomics, Proteomics, Microbiome Data, and Pathway Biology for Natural Product Therapeutics

Download PDF

Multi-omics phytopharmacology is emerging as a mechanism-centered strategy for interpreting the biological actions of plant-derived compounds, herbal extracts, natural product mixtures, and phytotherapeutic candidates. Rather than treating metabolite, transcript, protein, microbiome, or pathway signals as isolated evidence, this article develops an original integrative framework that connects compound-level characterization with biological-response evidence and validation-oriented interpretation. The framework positions metabolomics as a bridge between phytochemical exposure, endogenous metabolic response, and pathway perturbation, while transcriptomics is used to evaluate host gene-expression responses, regulatory programs, and pathway involvement. Proteomics adds protein-level evidence that may clarify functional pathway responses beyond transcript abundance, whereas microbiome data support interpretation of microbial metabolism, host–microbiome interactions, and natural product biotransformation. Pathway biology is treated as an interpretive layer rather than as proof of mechanism. The proposed logic emphasizes cross-omics convergence, exposure plausibility, quality control, feature annotation confidence, batch-effect awareness, safety consideration, and causal validation. The framework contributes a structured approach for transforming multi-omics observations into mechanistic hypotheses, validation priorities, and translational research decisions without overstating efficacy or causality. It supports more reproducible, exposure-aware, and biologically disciplined natural product therapeutics research.